Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Velesco Expands Operations with Massachusetts Office at the New QCI

Published: Friday, August 16, 2013
Last Updated: Friday, August 16, 2013
Bookmark and Share
Opening of new business development office in the greater Boston area.

Velesco Pharma has boosted its drug formulation, analytical development and cGMP clinical trial manufacturing services with the opening of a new business development office in the greater Boston area.

Velesco supports early stage drug development projects with a deeply experienced scientific team. Velesco is a CMC CRO, founded and staffed by pharmaceutical scientists with decades of experience in the industry.

“The growth of Velesco’s early phase CMC services has led to a need to increase our presence in this global hub for pharma and biotech companies. As we enter our 6th year of operations, we are looking forward to having a presence nearer to our existing and prospective clients,” said Gerry Cox, Velesco co-founder and chief operating officer, who will be leading the new office.

“In Massachusetts we invest in the life sciences because we are choosing to shape our own future,” said Governor Deval Patrick. “We welcome Velesco to Quincy’s new Innovation Center and look forward to them creating jobs and economic opportunities in the region.”

Velesco will be the first life sciences tenant of the Quincy Center for Innovation, a 12,500 square foot facility providing inexpensive and flexible office space and support services to assist start-up companies and aspiring entrepreneurs. The QCI is expected to open fully September 1st.

“One of the goals of the QCI is to provide a landing spot for those companies who are not yet located in Massachusetts, but have an interest and need to get acclimated to the region before choosing a permanent location,” said Donna Mavromates, Director of the Quincy Center for Innovation.

“Our economic future depends so much on creative partnerships, and I am thrilled that work done together by the Quincy Chamber, ENC, and the City has secured a first life science company at our innovation center with the kind of reputation for ingenuity as Velesco,” said City of Quincy Mayor Thomas P. Koch. “This is a tremendous first step, and I very much look forward to watching the innovation center continue to grow.”

“We will continue our focus on drug formulation, analytical method development and the supply of cGMP clinical supplies to early phase clinical trials while maintaining an evolving understanding of our clients needs. The Quincy Center for Innovation’s emphasis on working with young vibrant companies makes this location an excellent fit for Velesco.”

“We are excited to see Velesco expand their footprint here in Massachusetts by building out a presence where their clients and potential clients are doing business,” said Robert K. Coughlin, president & CEO of MassBio, the life sciences trade association. “Contract research and manufacturing is a vital piece of the new drug development paradigm and we are proud to be a hub for the world’s leading contract organizations.”

“We are thrilled to welcome Velesco to the fast-growing Massachusetts life sciences community,” said Susan Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center, the quasi-public agency tasked with implementing the state’s 10-year, $1-billion Life Sciences Initiative. “The company is a welcome addition, and we are pleased that Velesco selected Massachusetts as the best place for its new business development office. We are confident that Velesco, as a contract research and manufacturing organization, will find in Massachusetts the partners and client base they need to be successful.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos